bi-epitope DLL3 cCAR T
/ iCell Gene Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Preclinical evaluation of armored DLL3 biepitope compound nanobody CAR T cells
(AACR 2026)
- "The cCAR also demonstrated strong potency in SHP-77 xenograft mouse models.ConclusionsOur bi-epitope armored DLL3 cCAR T therapy demonstrated exceptional efficacy in vitro and in vivo. These results support future investigation of our cCAR in patients with SCLC and/or DLL3 expressing neuroendocrine tumors."
CAR T-Cell Therapy • IO biomarker • Preclinical • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3 • IL18
1 to 1
Of
1
Go to page
1